Lipid nanoparticles (LNPs) are the most advanced nonviral modality for nucleic acid (NA) delivery, and have recently gained enormous attention in the fields of RNA therapeutics and vaccine development. Here,… Click to show full abstract
Lipid nanoparticles (LNPs) are the most advanced nonviral modality for nucleic acid (NA) delivery, and have recently gained enormous attention in the fields of RNA therapeutics and vaccine development. Here, ionizable adamantane‐based lipidoids named XMaNs, which circumvent the usual need for laborious optimization of LNP components for highly diverse types of NAs, are described. The non‐toxic XMaN6 lipidoid is highly versatile in entrapment and delivery of siRNA, mRNA, plasmid DNA, and a cyclic dinucleotide. XMaN6‐based LNPs efficiently deliver: 1) siRNA into human primary hepatocytes and cell lines that are hard‐to‐transfect; 2) mRNA into mouse liver; 3) plasmid DNA; 4) 2′,3′‐cGAMP into cells and activated the cGAS‐STING pathway three orders of magnitude more efficiently than 2′,3′‐cGAMP alone. To our knowledge, such universality in delivering different NA types has not been previously described and can accelerate translation of LNPs into the clinic.
               
Click one of the above tabs to view related content.